Medicare Part D drugs will be chosen for price negotiation beginning this fall based on gross sales to the program, without taking rebates into account, according to a recent proposal by the Centers for Medicare and Medicaid Services.
CMS discussed the policy in its Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program and Medicare...







